Ningbo Menovo Pharmaceutical Co (SHSE:603538) Construction In Progress: ¥252 Mil (As of Mar. 2026)


SHSE:603538 Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
62 GF Score
Price ¥27.93
GF Value ¥22.32
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Ningbo Menovo Pharmaceutical Co Construction In Progress?

Ningbo Menovo Pharmaceutical Co SHSE:603538 -0.18% 62 Construction In Progress is ¥252 Mil as of Mar. 2026. GuruFocus rates SHSE:603538 with a GF Score™ of 62/100 and a GF Value™ of ¥22.32 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Ningbo Menovo Pharmaceutical Co's quarterly construction in progress declined from Sep. 2025 (¥407 Mil) to Dec. 2025 (¥272 Mil) and declined from Dec. 2025 (¥272 Mil) to Mar. 2026 (¥252 Mil).

Ningbo Menovo Pharmaceutical Co's annual construction in progress declined from Dec. 2023 (¥576 Mil) to Dec. 2024 (¥358 Mil) and declined from Dec. 2024 (¥358 Mil) to Dec. 2025 (¥272 Mil).

Ningbo Menovo Pharmaceutical Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Ningbo Menovo Pharmaceutical Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ningbo Menovo Pharmaceutical Co Construction In Progress Chart

Ningbo Menovo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 733.82 502.89 576.39 358.36 272.26

Ningbo Menovo Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 411.89 389.75 407.43 272.26 252.20
SHSE:603538
62GF Score
Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ningbo Menovo Pharmaceutical Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ¥252 Mil mean?
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a Construction In Progress of ¥252 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors.
Is Ningbo Menovo Pharmaceutical Co's Construction In Progress too high?
Ningbo Menovo Pharmaceutical Co's current Construction In Progress is ¥252 Mil. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's Construction In Progress compare to ZTS and UTHR?
Ningbo Menovo Pharmaceutical Co's Construction In Progress of ¥252 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors. Ningbo Menovo Pharmaceutical Co's current Construction In Progress is ¥252 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥22.32, compared to a current price of ¥27.93 — trading 25.1% above its estimated fair value. The current Construction In Progress is ¥252 Mil. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current Construction In Progress is ¥252 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?

Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥27.93 is trading 25.1% above its estimated GF Value™ of ¥22.32. GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:603538:

  • Construction In Progress: ¥252 Mil
  • GF Value™: ¥22.32 vs. price of ¥27.93 (25.1% above fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ningbo Menovo Pharmaceutical Co Business Description

Address No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
62GF Score

Get the complete analysis for SHSE:603538

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.93
Price
¥22.32
GF Value